Hypoxia-responsive lipid nanoparticles to balance placental factors in preeclampsia
Official title: Hypoxia-Responsive Lipid Nanoparticles for Regulation of Angiogenesis as a Therapeutic Strategy for Preeclampsia
Funded at Rowan University · NIH-11304911 · Data updated 2026-11-12
Aims to use tiny, targeted particles that release messages to the placenta to help restore healthy blood vessel growth in pregnancies affected by preeclampsia.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Rowan University NIH-funded |
| Lab location | 1 site (Glassboro, United States) |
| Project start | September 1, 2026 |
| Project end | August 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $408,380 |
| NIH project number | 1R21HD118230-01A1 |
| Project ID | NIH-11304911 on NIH RePORTER |
Who could benefit from this research
✓Could help
Pregnant individuals at risk for or diagnosed with preeclampsia, under obstetric care
✕Less likely to help
Pregnant individuals without preeclampsia or those outside the targeted gestational window may not benefit
What this research studies
Preeclampsia can endanger both mother and baby by causing high blood pressure and poor blood flow in the placenta. This project uses lipid nanoparticles that respond to low-oxygen conditions to deliver genetic material that nudges the placenta to promote healthy angiogenesis. The approach focuses on balancing harmful and helpful signals (like sFlt-1 and PlGF) to improve placental function. It emphasizes safety and feasibility in pregnancy while exploring a new therapeutic strategy. If successful, this could reduce complications and the need for early delivery related to preeclampsia.
Why it matters
Potential benefit: Potentially safer, more effective management of preeclampsia that could improve outcomes for mothers and babies.
How similar studies have gone: Other studies have explored placental targeting and angiogenesis, but this specific LNP-delivery of PlGF modulation in pregnancy is innovative and early-stage
Where this research is happening
-
Rowan University
Glassboro, United States Active
Researchers
- Principal investigator: Riley, Rachel — Rowan University
- Study coordinator: Riley, Rachel
Related research
Other NIH-funded projects on the same topics.
-
Using MRI to measure brain oxygen levels as an early sign of small vessel disease in the brain
This study is looking at how measuring oxygen levels in the brain with MRI can help spot early signs of small vessel disease, which is linked to memory problems and dementia, especially Alzheimer's, so if you're at risk due to age or high blood pressure, you might be able to participate in MRI scans to learn more about
-
HIF-driven ways to repair damaged lungs in IPF
A doctor-researcher is testing how low-oxygen signals (HIF) could help restore healthy lung tissue in people with IPF.
-
Ethical, multimodal AI for predicting preeclampsia risk in early pregnancy
A data-driven AI tool uses early-pregnancy information from medical records, ultrasound, and notes to predict preeclampsia risk and support safer pregnancy care.
-
Placental support cells and fetal red blood cell quality in preeclampsia
This grant studies how placental support cells in preeclampsia affect the development and quality of a baby’s red blood cells.
-
Epigenetic clues to preeclampsia in pregnancy
This grant explores how epigenetic changes and paternal factors may contribute to preeclampsia, a condition that can affect pregnancy health.
-
Neonatal Brain Injury Protection with New Purine Compounds
A new medication approach using purine derivatives is being studied to protect newborn brains from injury caused by limited blood flow and oxygen during birth.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.